---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024193"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:50:32.855006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Q3 net loss $8.7M; cash $77.2M, runway into Q1 2024; UPenn CAR-T partnership

## Summary
- Net loss $8.7M vs $16.2M in Q3 2021; improvement driven by non-cash warrant liability changes.
- Cash and equivalents $77.2M as of Sep 30, 2022; expected to fund operations into Q1 2024.
- R&D expenses $5.4M, G&A $3.5M; increases due to higher headcount, clinical studies, and public company costs.
- European Commission granted orphan drug designation for CAN-2409 in glioma; phase 3 protocol submitted.
- Partnered with UPenn Center for Cellular Immunotherapies to study viral immunotherapy + CAR-T in solid tumors.

## SEC filing metadata
- accession: 0000950170-22-024193
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/0000950170-22-024193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/cadl-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024193
- JSON: https://secwatch.observer/filing/0000950170-22-024193.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024193.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $31,000, net income $8.7 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $31,000
  - Net income: $8.7 million
  - Result: reported results
  source text: Research and Development Service Revenue, related party: Research and Development Service Revenue, related party, for the third quarters ended September 30, 2022 and 2021 was $31,000. Research and Development Expenses: Research and development expenses were $5.4 million for the quarter ended September 30, 2022 compared to $5.3 million for the comparable
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/0000950170-22-024193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.